secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001193125-25-051441
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports Q4/FY 2024 results; cash $55.3M, AbbVie collaboration adds $52M upfront
--------------------------------------------------------------------------------

- Net loss of $13.1M in Q4 2024, $58.2M for FY 2024; license revenue $6.3M from Gilead deal.
- Cash $55.3M at Dec 31, 2024; plus $52M AbbVie upfront in Q1 2025 extends runway into Q1 2026.
- Vilastobart Phase 2 in MSS CRC: 27% ORR in patients without liver metastases; colitis 5%.
- Collaboration with AbbVie: up to $2.1B total payments plus royalties; develop masked T cell engagers.
- Plan to nominate development candidates for PSMA (Q3 2025), CLDN18.2 (Q4 2025), STEAP1 (H1 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525051441/0001193125-25-051441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525051441/d890896d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-051441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer